12561 Pitfalls Of ACR-TIRADS Guidelines for Thyroid Nodules: A Case Study Of Malignant Transformation in a Patient with Graves Disease

Maria Mathiopoulou
DOI: https://doi.org/10.1210/jendso/bvae163.2037
2024-10-01
Journal of the Endocrine Society
Abstract:Abstract Disclosure: M. Mathiopoulou: None. Introduction: The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) provides standardized guidelines for the assessment and management of thyroid nodules based on ultrasound characteristics. However, the application of these guidelines in patients with Graves disease and evolving nodules presents unique challenges, as illustrated by the following case study. Case Presentation: We present the case of a 30-year-old female patient diagnosed with Graves' disease, who initially presented with two thyroid nodules. The first nodule, classified as ACR-TIRADS 5 and measuring up to 1 cm in the right thyroid lobe, underwent biopsy at the initial assessment, revealing no signs of malignancy. Subsequent ultrasound imaging performed after a 1.5-year interval showed no changes in size or characteristics. However, the second nodule, also located in the right lobe, exhibited newly developed macro- and microcalcifications during the follow-up period, resulting in an upgrade from ACR-TIRADS 4 to ACR-TIRADS 5. Despite its small size (< 1 cm), the evolving characteristics prompted a biopsy, which revealed features consistent with papillary carcinoma. Following total thyroidectomy, histopathological analysis confirmed the presence of papillary carcinoma in both nodules.Discussion: This case underscores the importance of cautious interpretation of ACR TI-RADS guidelines in patients with Graves disease and thyroid nodules. While these guidelines provide valuable risk stratification, they may not fully capture the dynamic nature of nodules in the context of autoimmune thyroid disease. Malignant transformation can occur even in nodules that appear stable or demonstrate benign characteristics on imaging. Therefore, clinicians should exercise clinical judgment and consider additional factors, such as clinical history, biochemical markers, and individualized risk assessment, when managing thyroid nodules in patients with Graves disease. Conclusion: The case highlights the limitations and potential pitfalls of relying solely on ACR TI-RADS guidelines for risk stratification of thyroid nodules, particularly in patients with Graves disease. Clinicians should approach the evaluation and management of thyroid nodules in this population with caution, considering the dynamic nature of nodules and the possibility of malignant transformation despite apparent stability on imaging. Presentation: 6/2/2024
What problem does this paper attempt to address?